Physicians and regulators are concerned that changes to a patient’s genome might have unintended, life-altering consequences
It will be imperative to understand the off-target risk profile of your therapy to inform regulatory filings, support patient and clinician decision making, and to conduct post market surveillance
Invaluable gene editing off-target insights from initial research to patient therapies
Through every phase of development, our portfolio of solutions assesses and identifies both on-target specificity and off-target risks to support research and development, inform study design, enable clinical trial enrollment, and ensure access to therapy in the clinic.
SeQure Dx comprehensively evaluates and confirms on- and off-target events using proprietary analytical tools that deliver unparalleled sensitivity and scalability.
Our diagnostics are editor-agnostic and scalable — providing both individual and population level insight.
Join the team – help us make safe gene editing a reality
Come join an energetic, focused, and dynamic team that supports career growth as well as personal well-being.
-
03.18.24 || 9 top CRISPR breakthroughs of the past year
The world of gene editing is one where the impossible becomes possible, and the future of healthcare is being rewritten before our eyes. CRISPR and other gene editing based therapeutics represent a transformative step in healthcare, moving us from an age of treatment and living with disease, to one of cure. In the last year […]Full Release ❯
-
02.26.24 || Reflecting on a year of achievements and learning at SeQure Dx
As the calendar flips to 2024, we at SeQure Dx find ourselves at an exhilarating crossroads. With a year of groundbreaking achievements behind us and the horizon filled with promising opportunities, we're eager to share our journey and the future we're passionately working towards.Full Release ❯